Gadoteridol
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| Other names | (10-(2-(hydroxy-κO)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3−)-κN1,κN4,κN7,κN10,κO1,κO4,κO7)-gadolinium |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration |
IV |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H29GdN4O7 |
| Molar mass | 558.69 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
|
| |
Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance.
- Bracco Diagnostic Inc. (May 2007). "Gadoteridol (ProHance) prescribing information (revised May 2007)". DailyMed. U.S. National Library of Medicine. Retrieved 2008-07-13.
| X-ray and CT |
|
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRI |
|
||||||||||||
| Ultrasound |
|
||||||||||||
| |||||||||||||